A Welcome from the Editorial Board
Patient case study: Clinical Presentation of ADA Deficiency
Lymphoproliferative disorders not uncommon in ADA-SCID patients
Short- and medium-term safety profile of ADA-SCID gene therapy described
Vector-transduced cell tracking feasible in gene therapy-treated ADA-SCID patients
Metabolic, not microbial, pathogenesis likely for ADA-SCID lung disease
The 26th Anniversary Congress of the European Society for Gene & Cell Therapy.
Annual meeting of the European Society for Immunodeficiencies.